Investigational New Drugs

, Volume 34, Issue 5, pp 663–676 | Cite as

Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine–induced apoptosis in neuroblastoma cells

  • Jennifer C. LennonEmail author
  • Stefania Butini
  • Giuseppe Campiani
  • Anne O’Meara
  • D. Clive Williams
  • Daniela M. Zisterer


Neuroblastoma, a paediatric malignancy of the sympathetic nervous system, accounts for 15 % of childhood cancer deaths. Despite advances in understanding the biology, it remains one of the most difficult paediatric cancers to treat partly due to the development of multidrug resistance. There is thus a compelling demand for new treatment strategies that can bypass resistance mechanisms. The pyrrolo-1,5-benzoxazepine (PBOX) compounds are a series of novel microtubule-targeting agents that potently induce apoptosis in various tumour models. We have previously reported that PBOX compounds induce apoptosis in drug sensitive and multidrug resistant neuroblastoma cells and synergistically enhance apoptosis induced by chemotherapeutics such as carboplatin. In this study we present further data concerning the molecular basis of PBOX-induced apoptosis in neuroblastoma. We demonstrate that PBOX-6 induced AMP-activated protein kinase (AMPK) activation and downstream acetyl-CoA carboxylase phosphorylation. Increased reactive oxygen species (ROS) appeared to serve as the upstream signal for AMPK activation as pretreatment of cells with the antioxidant N-acetylcysteine inhibited both AMPK activation and PBOX-induced apoptosis. Furthermore, activation of AMPK by PBOX-6 was found to inhibit mTOR complex 1 (mTORC1) signalling. Finally, we demonstrate the efficacy of PBOX-6 in an in vivo xenograft model of neuroblastoma. This study provides new insights into understanding the molecular and cellular mechanisms involved in PBOX-induced cell death in neuroblastoma and further supports their future use as novel anti-cancer agents for the treatment of neuroblastoma.





Acetyl Co-A carboxylase


5’ adenosine monophosphate-activated protein kinase


Chronic myeloid leukaemia




Eukaryotic elongation factor 2


Fluorescence associated cell sorter


Foetal bovine serum


Hydrogen peroxide


Myeloid cell leukemia 1


Multidrug resistance


Microtubule targeting agent


Mammalian target of rapamycin




Reactive oxygen species


Poly (ADP-ribose) polymerase


Phosphate buffered saline





Stefania Butini would like to thank Istituto Toscano Tumori. This study was funded by the National Children’s Research Centre, Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202–2211CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cheung NK, Dyer MA (2013) Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 13(6):397–411CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Saraswathy M, Gong S (2013) Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 31(8):1397–1407CrossRefPubMedGoogle Scholar
  4. 4.
    Zisterer DM, Campiani G, Nacci V, Williams DC (2000) Pyrrolobenzoxazepines induce apoptosis in HL-60, Jurkat and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther 293(1):48–59PubMedGoogle Scholar
  5. 5.
    Greene LM, Fleeton M, Mulligan J, Gowda C, Sheahan BJ, Atkins GJ et al (2005) The pyrrolo-1, 5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status, and inhibits breast tumour growth in vivo. Oncol Rep 14(5):1357–1363PubMedGoogle Scholar
  6. 6.
    Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G et al (2006) Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol 70(1):60–70PubMedGoogle Scholar
  7. 7.
    Nathwani SM, Butler S, Fayne D, McGovern N, Sarkadi B, Meegan MJ et al (2010) Novel microtubule targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug resistant (MDR) cancer cells. Cancer Chemother Pharmacol 66(3):585–596CrossRefPubMedGoogle Scholar
  8. 8.
    Nathwani SM, Cloonan SM, Stronach M, Campiani G, Lawler M, Williams DC et al (2010) Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells. Oncol Rep 24(6):1499–1507CrossRefPubMedGoogle Scholar
  9. 9.
    Bright SA, McElligott AM, O’Connell JW, O’Connor L, Carroll P, Campiani G et al (2010) Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer 102(10):1474–1482CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Bright SA, Campiani G, Deininger MW, Lawler M, Williams DC, Zisterer DM (2010) Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. Biochem Pharmacol 80(1):31–38CrossRefPubMedGoogle Scholar
  11. 11.
    McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV et al (2009) The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 69(21):8366–8375CrossRefPubMedGoogle Scholar
  12. 12.
    Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM (2009) The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Biochem Pharmacol 77:310–321Google Scholar
  13. 13.
    Lennon JC, Bright SA, Carroll E, Butini S, Campiani G, O’Meara A et al (2014) The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells. Biochem Pharmacol 87(4):611–624CrossRefPubMedGoogle Scholar
  14. 14.
    Pradelli LA, Bénéteau M, Chauvin C, Jacquin MA, Marchetti S, Muñoz-Pinedo C et al (2010) Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29(11):1641–1652CrossRefPubMedGoogle Scholar
  15. 15.
    Chen MB, Shen WX, Yang Y, Wu XY, Gu JH, Lu PH (2011) Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 226(7):1915–1925CrossRefPubMedGoogle Scholar
  16. 16.
    Chen MB, Zhang Y, Wei MX, Shen W, Wu XY, Yao C et al (2013) Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells. Cell Signal 25(10):1993–2002CrossRefPubMedGoogle Scholar
  17. 17.
    Wu WD, Hu ZM, Shang MJ, Zhao DJ, Zhang CW, Hong D et al (2014) Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signalling in GBC-SD gallbladder cancer cells. Int J Mol Sci 15(7):12778–12790CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H et al (2010) Hydrogen peroxide inhibits mTOR signaling by activation of AMPK alpha leading to apoptosis of neuronal cells. Lab Investig 90(5):762–773CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48(6):749–762CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kerksick C, Willoughby D (2005) The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J Int Soc Sports Nutr 2:38–44CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bitting RL, Armstrong AJ (2013) Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 20(3):R83–R99CrossRefPubMedGoogle Scholar
  22. 22.
    Vinayak S, Carlson RW (2013) mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park) 27(1):38–44Google Scholar
  23. 23.
    Barrett D, Brown VI, Grupp SA, Teachey DT (2012) Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs 14(5):299–316PubMedPubMedCentralGoogle Scholar
  24. 24.
    Matter MS, Decaens T, Andersen JB, Thorgeirsson SS (2014) Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 60(4):855–865CrossRefPubMedGoogle Scholar
  25. 25.
    Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B et al (2008) Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27(20):2910–2922CrossRefPubMedGoogle Scholar
  26. 26.
    Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Ciani SM et al (1996) Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific ‘peripheral-type’ benzodiazepine receptor ligands. J Med Chem 39(18):3435–3450CrossRefPubMedGoogle Scholar
  27. 27.
    Williams CR, Tabiosa R, Linehana WM, Neckersa L (2007) Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 178:1528–1532CrossRefPubMedGoogle Scholar
  28. 28.
    Shah MR, Kriedt CL, Lents NH, Hoyer MK, Jamaluddin N, Klein C et al (2009) Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res 28:84CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Beck MT, Chen NY, Franek KJ, Chen WY (2003) Experimental therapeutics prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res 63:3598–3604PubMedGoogle Scholar
  30. 30.
    Garcia-Gil M, Pesi R, Perna S (2003) 5’-aminoimidazole-4-carboxamide riboside induces apoptosis in human neuroblastoma cells. Neuroscience 117:811–820CrossRefPubMedGoogle Scholar
  31. 31.
    Hadad SM, Appleyard V, Thompson AM (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 114:391CrossRefPubMedGoogle Scholar
  32. 32.
    Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW et al (2011) Metformin inhibits P-glycoprotein expression via the NF-kB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162(5):1096–1108CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS et al (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30(2):214–226CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA et al (2011) The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. J Endocrinol 211(1):79–85CrossRefGoogle Scholar
  35. 35.
    Arsikin K, Kravic-Stevovic T, Jovanovic M, Ristic B, Tovilovic G, Zogovic N et al (2012) Autophagy-dependent and -independent involvement of AMP-activated protein kinase in 6-hydroxydopamine toxicity to SH-SY5Y neuroblastoma cells. Biochim Biophys Acta 1822(11):1826–1836CrossRefPubMedGoogle Scholar
  36. 36.
    Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B et al (2009) Mcl-1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 8(16):1587–1595CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251–262CrossRefPubMedGoogle Scholar
  38. 38.
    Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282:32539–32548CrossRefPubMedGoogle Scholar
  39. 39.
    Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25(18):1895–1908CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8:774–785CrossRefPubMedGoogle Scholar
  41. 41.
    Jones RG, Plas DR, Kubek S et al (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283–293CrossRefPubMedGoogle Scholar
  42. 42.
    Liang J, Shao SH, Xu ZX et al (2007) The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9:218–224CrossRefPubMedGoogle Scholar
  43. 43.
    Hwang PM, Bunz F, Yu J, Rago C et al (2001) Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 7:1111–1117CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Pelicano H, Carney D, Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97–110CrossRefPubMedGoogle Scholar
  45. 45.
    Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W et al (2003) Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278:37832–37839CrossRefPubMedGoogle Scholar
  46. 46.
    Conklin KA (2004) Free radicals: the pros and cons of antioxidants. Cancer chemotherapy and antioxidants. J Nutr 134:3201–3204, ISSN 0022–3166Google Scholar
  47. 47.
    Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87(1):245–313CrossRefPubMedGoogle Scholar
  48. 48.
    Paletta-Silva R, Rocco-Machado N, Meyer-Fernandes JR (2013) NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicity. Int J Mol Sci 14(2):3683–3704CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67(8):3512–3517CrossRefPubMedGoogle Scholar
  50. 50.
    Mc Gee MM, Campiani G, Ramunno A, Nacci V, Lawler M, Williams DC et al (2002) Activation of the c-Jun NH2 terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J Biol Chem 227(21):18383–18389CrossRefGoogle Scholar
  51. 51.
    Han JE, Choi JW (2012) Control of JNK for an activation of NADPH oxidase in LPS-stimulated BV2 microglia. Arch Pharm Res 4:709–715CrossRefGoogle Scholar
  52. 52.
    Ling LU, Tan KB, Lin H, Chiu GN (2011) The role of reactive oxygen species and autophagy in safingol-induced cell death. Cell Death Dis 2:e129CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Wu YJ, Muldoon LL, Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312(2):424–431CrossRefPubMedGoogle Scholar
  54. 54.
    Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279CrossRefPubMedGoogle Scholar
  55. 55.
    Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J (1998) Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 8(2):69–81CrossRefPubMedGoogle Scholar
  56. 56.
    Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM (2013) FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res 73(7):2189–2198CrossRefPubMedGoogle Scholar
  57. 57.
    Horman S, Beauloye C, Vertommen D, Vanoverschelde JL, Hue L, Rider MH (2003) Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2. J Biol Chem 278:41970–41976CrossRefPubMedGoogle Scholar
  58. 58.
    Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L et al (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12:1419–1423CrossRefPubMedGoogle Scholar
  59. 59.
    Liu G, Wang R, Wang Y, Li P, Zhao G, Zhao L et al (2013) Ethacrynic acid oxadiazole analogs induce apoptosis in malignant hematologic cells through downregulation of Mcl-1 and c-FLIP, which was attenuated by GSTP1-1. Mol Cancer Ther 12(9):1837–1847CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Jennifer C. Lennon
    • 1
    • 2
    Email author
  • Stefania Butini
    • 3
  • Giuseppe Campiani
    • 3
  • Anne O’Meara
    • 4
  • D. Clive Williams
    • 1
  • Daniela M. Zisterer
    • 1
  1. 1.School of Biochemistry and Immunology, Trinity Biomedical Sciences InstituteTrinity College DublinDublin 2Ireland
  2. 2.The National Children’s Research CentreDublinIreland
  3. 3.European Research Centre for Drug Discovery & Development (NatSynDrugs)University of SienaSienaItaly
  4. 4.Our Lady’s Children’s HospitalDublin 12Ireland

Personalised recommendations